J Korean Med Sci.  2017 Jan;32(1):22-28. 10.3346/jkms.2017.32.1.22.

Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children

• Yoo RN
• Kim SH
• Lee J

• KMID: 2417580
• DOI: http://doi.org/10.3346/jkms.2017.32.1.22

Abstract

It is important to use vancomycin in a proper manner to ensure optimal drug exposure. Despite extensive use of vancomycin in children, studies on its optimal trough concentration (C(trough)) in the pediatric population remained rare. This retrospective study included children < 18 years old with culture-confirmed methicillin-resistant Staphylococcus aureus (MRSA) bacteremia who were hospitalized in our institute from January 2010 to April 2014. Clinical characteristics, initial vancomycin dose, Ctrough and clinical/microbiological outcomes were retrospectively collected from medical records. Forty-six MRSA bacteremia cases occurring to the patients with a mean age of 22.0 ± 46.9 months were included and all of them were healthcare-associated. Severe diseases requiring intensive care unit (ICU) stay, mechanical ventilation and/or resulting in death were observed in 57.8% (26/45); all-cause 30-day fatality was 11.1% (5/45). An initial C(trough) ≥ 15 μg/mL was achieved in only 4 (8.7%) cases with an average vancomycin dosage of 40.6 ± 7.9 mg/kg/day. Persistent bacteremia at 48 hours after initiation of vancomycin was observed more frequently in children with initial Ctrough < 10 μg/mL than in those with C(trough) < 10 μg/mL (P = 0.032). However, there was no statistically significant difference between the two groups in terms of 30-day mortality and recurrent bacteremia (P = 0.899, and P = 0.754, respectively). Although initial C(trough) may be a useful parameter for minimizing early microbiological failure, it does not predict 30-day fatality or recurrence in pediatric MRSA bacteremia. Further prospective data on vancomycin dosing are needed to find the optimal drug exposure and clarify its impact on clinical outcomes in pediatric populations.

Keyword

MRSA Bacteremia; Vancomycin Concentration; Children; Korea

MeSH Terms

Bacteremia*
Child*
Humans
Intensive Care Units
Korea
Medical Records
Methicillin Resistance*
Methicillin-Resistant Staphylococcus aureus*
Mortality
Prospective Studies
Recurrence
Respiration, Artificial
Retrospective Studies
Vancomycin*
Vancomycin

Reference

1. Chen SY, Hsueh PR, Chiang WC, Huang EP, Lin CF, Chang CH, Chen SC, Chen WJ, Chang SC, Lai MS, et al. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia. J Infect. 2014; 69:259–265.

2. Suryadevara M, Steidl KE, Probst LA, Shaw J. Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs. J Pediatr Pharmacol Ther. 2012; 17:159–165.

3. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43:925–942.

4. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011; 52:285–292.

5. Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, Cho S, Natale S, Bui I, Tran TM, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013; 32:e155–63.

6. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J. 2013; 32:1077–1079.

7. Frymoyer A, Hersh AL, El-Komy MH, Gaskari S, Su F, Drover DR, Van Meurs K. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Antimicrob Agents Chemother. 2014; 58:6454–6461.

8. Welsh KJ, Abbott AN, Lewis EM, Gardiner JM, Kruzel MC, Lewis CT, Mohr JF, Wanger A, Armitige LY. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin. J Clin Microbiol. 2010; 48:894–899.

9. Taketomo CK, Hodding JH, Kraus DM. Pediatric and Neonatal Dosage Handbook. 18th ed. Hudson, OH: Lexi-Comp;2011.

10. Centers for Disease Control and Prevention (US). Bloodstream Infection Event (Central Line-associated Bloodstream Infection and Non-central Line-associated Bloodstream Infection). Atlanta, GA: Centers for Disease Control and Prevention;2016. p. p4:1–p4:32.

11. Sung JY, Lee J, Choi EH, Lee HJ. Changes in molecular epidemiology of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Korean children. Diagn Microbiol Infect Dis. 2012; 74:28–33.

12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18:268–281.

13. Kim CJ, Kim HB, Oh MD, Kim Y, Kim A, Oh SH, Song KH, Kim E, Cho Y, Choi Y, KIND Study group (Korea Infectious Diseases Study group), et al. The burden of nosocomial staphylococcus aureus bloodstream infection in South Korea: a prospective hospital-based nationwide study. BMC Infect Dis. 2014; 14:590.

14. Song KH, Kim ES, Sin HY, Park KH, Jung SI, Yoon N, Kim DM, Lee CS, Jang HC, Park Y, Korea INfectious Diseases (KIND) study group, et al. Characteristics of invasive Staphylococcus aureus infections in three regions of Korea, 2009-2011: a multi-center cohort study. BMC Infect Dis. 2013; 13:581.

15. Patel K, Crumby AS, Maples HD. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC? Paediatr Drugs. 2015; 17:97–103.

16. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009; 28:398–402.

17. Le J, Ngu B, Bradley JS, Murray W, Nguyen A, Nguyen L, Romanowski GL, Vo T, Capparelli EV. Vancomycin monitoring in children using bayesian estimation. Ther Drug Monit. 2014; 36:510–518.

18. Hahn A, Frenck RW Jr, Zou Y, Vinks AA. Validation of a pediatric population pharmacokinetic model for vancomycin. Ther Drug Monit. 2015; 37:413–416.

19. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012; 54:755–771.

20. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC Jr, Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis. 2009; 199:532–536.

21. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011; 204:340–347.

22. Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young DC, Olson J, Noyes BE, Ampofo K, Spigarelli MG. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis. Pharmacotherapy. 2013; 33:1288–1296.